Pharmaceutical Executive Daily: New Research on Ozempic
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
Key Updates
- FDA approval of Bayer’s Lynkuet for menopausal hot flashes
- New research suggesting Ozempic may reduce biological age
- Novartis’ $12 billion merger agreement to acquire Avidity Biosciences
Lynkuet Approval
The FDA has approved Bayer’s Lynkuet, also known as elinzanetant, as the first dual neurokinin 1 and 3 receptor antagonist for the treatment of moderate to severe vasomotor symptoms associated with menopause.
The approval is based on Phase III OASIS trial data showing significant reductions in hot flash frequency and severity.
As a non-hormonal option, Lynkuet provides an important new therapeutic alternative for patients seeking relief from menopausal symptoms without estrogen exposure.
Author's summary: New research on Ozempic and Lynkuet approval.
More News
- Art the Clown Owes One of His 'Terrifier' Actresses a Lot of Money
- NGP-backed Cygnet Energy to buy Kiwetinohk Energy for $1bn | PE Hub
- Novacap invests in wireless tower infrastructure developer TAG Towers | PE Hub
- 9 Black Actresses Who Went From Broadway To The Hollywood Big Screen
- Glowing sperm helps to reveal secrets of mosquito sex
- US passport support in Apple Wallet is a hugely important step
- New president of The Church of Jesus Christ of Latter-day Saints inherits a global faith far more diverse than many realize – Baptist News Global
- Gavin Newsom Says He Has 'No Interest' in Appearing on Joe Rogan's Podcast: 'I'm Moving On' | Video
- Material Trends in Space: What Rockets are Made of (and More)
- Elon Musk's Grokipedia: Just Another Wikipedia Clone or Something More?